Edwards Lifesciences rated buy due to FDA approvals and strong cardiology niche performance.

Edwards Lifesciences received a buy rating based on recent FDA approvals, a specialized portfolio in cardiology, and strong operating margins and cash flow. Despite underperforming key benchmarks this year, the company's focus on heart-related medical devices positions it well for future growth. However, investors should consider sector risks related to FDA regulations and product impacts on patients. The company's market cap exceeds $51 billion, highlighting its significant presence in the healthcare sector.

Edwards Lifesciences (EW) shares are trading at USD 92.76, up 1.07% as of Oct 29, 2026 18:41 WIB on Pluang. The stock's market cap stands at $52.90 billion, reflecting its strong position in the healthcare sector. Trading volume reached 2,296,559 shares, indicating active investor interest.